NEW YORK, March 2 - Tartu, Estonia may seem an unlikely launch point for a global assault on the SNP chip market. But Asper Biotech, a small Estonian microarray startup, hopes to leverage its unique chip-based sequencing technology to do just that. 

"Asper's edge is that manufacturing on a chip and reagent costs are way lower," than other SNP sequencing methods, said Kalev Kask, director of Asper's US office. "Our cost is definitely below 50 cents a SNP right now."  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.